WO2011080684A1 - Process for the preparation of candesartan cilexetil - Google Patents
Process for the preparation of candesartan cilexetil Download PDFInfo
- Publication number
- WO2011080684A1 WO2011080684A1 PCT/IB2010/056066 IB2010056066W WO2011080684A1 WO 2011080684 A1 WO2011080684 A1 WO 2011080684A1 IB 2010056066 W IB2010056066 W IB 2010056066W WO 2011080684 A1 WO2011080684 A1 WO 2011080684A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- process according
- solvent
- mixtures
- temperature
- candesartan
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention provides an improved process for the preparation of
- candesartan and pharmaceutically acceptable salts and esters thereof for use in the treatment of hypertension and related diseases are examples of candesartan and pharmaceutically acceptable salts and esters thereof for use in the treatment of hypertension and related diseases.
- Candesartan cilexetil of Formula I is a prodrug and is chemically described as ( ⁇ )-l- Hydroxyethyl-2-ethoxy- 1 - [p-(o- lHtetrazol-5-ylphenyl)benzyl] -7-benzimidazole carboxylate, cyclohexyl carbonate (ester). It is a selective angiotensin II receptor antagonist and is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents and is represented by the structural Formula I as shown below.
- U.S. Patent Nos. 5,196,444 and 5,578,733 describe the removal of a trityl protecting group of the N-protected tetrazolyl compounds using methanol in the presence of a mineral acid, such as hydrochloric acid, which requires complex extractions or chromatographic purification to produce pure candesartan cilexetil.
- U.S. Patent No. 7,345,072 describes the deprotection of tetrazolyl compounds, including candesartan cilexetil, in the presence of an anhydrous mineral acid or aqueous mineral acid at a concentration higher than 20% w/w.
- the strong acidic conditions produce more decomposition products and thereby reduces the overall purity of the final product.
- WO 05/021535 discloses the preparation of candesartan cilexetil by the deprotection of trityl moiety at a reflux temperature in the presence of anhydrous Ci to C 5 alcohol under neutral or slightly basic conditions involving longer reaction time (for e.g. stirring for several hours, such as 18-24 hours); this is followed by removal of the triphenylmethylether moiety precipitated as a solid, and thereby increases the number of reaction steps.
- WO 05/037821 describes the deprotection of the trityl candesartan cilexetil by the use of methane sulphonic acid, p-toluene sulphonic acid, formic and trifluoroacetic acid in solvent mixture or by refluxing candesartan cilexetil in mixture of toluene, water, and methanol.
- the initial product obtained by these procedures is mostly a viscous oil or a semi solid, which is difficult to handle.
- WO 07/074399 and WO 07/042161 disclose the preparation of candesartan cilexetil from trityl candesartan cilexetil involving Lewis acids such as boron trifluoride, zinc chloride, aluminium trihalide, or titanium tetrachloride which are costly and thus are not commercially viable.
- the present invention provides for a process for the preparation of candesartan or its derivatives.
- the process includes:
- the alcoholic solvent used in step (a) may include methanol, ethanol, n-propanol, n- butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and/or mixtures thereof.
- the second solvent may be chloroform, dichloromethane, carbon tetrachloride, ethylene dichloride and/or mixtures thereof.
- the heating of the reaction mixture is carried out at the temperature from about 35°C to about reflux temperature.
- the stirring of the reaction mixture is carried out from about 1 hour to about 10 hours.
- the isolation of the solid obtained in step (d) involves purification from a suitable organic solvent that includes the heating of the mixture at the temperature from about 25°C to about 45°C.
- the suitable organic solvent may be either ethers and/or hydrocarbon solvents.
- the ether may be methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane and/or mixtures thereof.
- the hydrocarbon solvent may be pentane, hexane, n-heptane, n-octane,
- the drying of the solid is carried out in air at a temperature from about 30°C to about 60°C.
- the purification from a ketonic solvent or a mixture with water involves heating from about 35°C to about 50°C.
- the ketonic solvent is selected from the group of acetone, 2- butanone, 2-pentanone, 3-pentanone, 2-hexanone, 2-heptanone, 2-octanone and/or mixtures thereof.
- the isolation of the solid includes the cooling of the reaction mixture from about 0°C to about 15°C.
- the isolation may further include drying the solid in air at the temperature from about 30°C to about 50°C.
- the present invention includes a process for the preparation of candesartan or its derivatives.
- the process includes:
- Embodiments of this aspect may include one or more of the following features.
- the alcoholic solvent used in step (a) may be methanol, ethanol, n-propanol, n- butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and/or mixtures thereof.
- the second solvent includes chloroform, dichloromethane, carbon tetrachloride, ethylene dichloride and/or mixtures thereof.
- the heating of the reaction mixture is carried out at the temperature from about 35°C to about reflux temperature.
- the stirring of the reaction mixture is carried out from about 1 hour to about 10 hours.
- the isolation of the solid obtained in step (b) involves purification from a suitable organic solvent that includes the heating of the mixture at the temperature from about 25 °C to about 45 °C.
- the suitable organic solvent may be ethers and/or hydrocarbon solvents.
- the ether may be methyl tertiary butyl ether, tetrahydrofuran, 1,4- dioxane and/or mixtures thereof.
- the hydrocarbon solvent may be pentane, hexane, n- heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene or o, m, p- xylenes.
- the purification from a ketonic solvent or its mixture with water involves heating from about 35°C to about 50°C.
- the ketonic solvent is selected from the group of acetone, 2- butanone, 2-pentanone, 3-pentanone, 2-hexanone, 2-heptanone, 2-octanone and/or mixtures thereof.
- the isolation of the solid includes the cooling of the reaction mixture from about 0°C to about 15°C.
- the process further includes drying the solid in air at the temperature from about 30°C to about 50°C.
- the present invention provides for candesartan cilexetil comprising HPLC purity greater than 99% and desethyl impurity content less than 0.2%.
- the present invention provides for a process for the preparation of candesartan or its derivatives, which includes the steps of:
- the alcoholic solvent can be selected from methanol, ethanol, n-propanol, n-butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol or a mixture thereof.
- the second solvent in step (b) can be selected from chloroform, dichloromethane, carbontetrachloride, ethylene dichloride and/or mixtures thereof.
- the present invention also included candesartan or its derivatives as obtained above, including candesartan cilexetil containing a desethyl impurity content less than 0.6%, preferably less than 0.5% and a purity greater than or equal to about 98% when measured by HPLC area percentage.
- Candesartan or its derivatives may be purified from a ketonic solvent or their mixtures and/or a mixture with water.
- Derivatives of candesartan herein refers to pharmaceutically acceptable salts and esters.
- reaction mixture containing a tetrazolyl protected derivative of candesartan in an alcoholic solvent or their mixtures in the presence of iodine can be heated from about 35°C to about reflux temperature followed by stirring.
- the term "about” when used in reference to defined parameter like temperature indicates inherent variability in, for example, measuring the parameter or achieving the parameter and refers to variation by +5°C.
- Reflux temperature herein refers to the temperature at which solvent/solvent mixture starts boiling.
- tetrazolyl protecting group may include, but is not limited groups including optionally substituted multiphenylmethyl groups (e.g., triphenylmethyl (trityl), 4-methoxy triphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4"- trimethoxytriphenyl methyl, 4,4'-dimethoxydiphenyl methyl and the like), 2- nitrobenzenesulfenyl and benzhydryl.
- multiphenylmethyl groups e.g., triphenylmethyl (trityl), 4-methoxy triphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4"- trimethoxytriphenyl methyl, 4,4'-dimethoxydiphenyl methyl and the like
- 2- nitrobenzenesulfenyl and benzhydryl e.g., 2- nitrobenzenesulfenyl and benzhydryl.
- the solution of iodine in an alcoholic solvent or mixtures thereof can be prepared at room temperature (25 °C to 30°C) or by heating.
- Alcoholic solvent may include Ci-C 8 straight or branched chain alcohols which can be primary, secondary, tertiary, comprising of methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutanol, ter-butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and the like.
- Ci-C 8 straight or branched chain alcohols which can be primary, secondary, tertiary, comprising of methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutanol, ter-butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and the like.
- the second solvent used herein is a halogenated solvent which may be optionally added to the alcoholic mixture of tetrazolyl-protected candesartan and iodine, examples of which may include chloroform, dichloromethane, carbontetrachloride, ethylene dichloride and/or mixtures thereof. It is generally observed that the addition of the second solvent helps in increasing the final purity of the candesartan or its derivatives including candesartan cilexetil.
- the stirring of the above reaction mixture containing the tetrazolyl protected derivative of candesartan and iodine in an alcoholic solvent may be carried out for about 1 hour to about 10 hours to get a clear solution at the same temperature. Stirring time may be changed accordingly, depending upon the temperature used for heating by a person of ordinary skill in the art.
- the solvent/solvent mixture may be removed to get the residual solid material.
- the removal of the solvent/solvent mixture may be carried out by any means known to a person of ordinary skill in the art, including for example concentration, evaporation or distillation.
- the residual solid material can be further dissolved in a halogenated solvent followed by washing with an aqueous sodium thiosulfate solution and de-ionized water.
- a halogenated solvent examples are as described above.
- the organic layer so obtained may be dried over sodium sulfate and concentrated under reduced pressure and/or optionally charcolized with active carbon. This is followed by filtration over hyflobed to get solid mass, which then may be further dissolved in a suitable organic solvent, for purification from about ambient temperature to about 45 °C and stirred for about 7 hours to about 15 hours at the same temperature.
- Ambient temperature herein refers to room temperature (25°C to 30°C).
- suitable organic solvents may include ethers, such as, methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane or aliphatic, alicyclic and aromatic hydrocarbons, such as, pentane, hexane, n-heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene, o, m, p-xylenes and the like.
- ethers such as, methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane or aliphatic, alicyclic and aromatic hydrocarbons, such as, pentane, hexane, n-heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene, o, m, p
- the product obtained after stirring can be isolated by any conventional means known to a person of ordinary skill in the art including decantation, filtration or centrifugation.
- the isolated solid can be dried under vacuum and/or air or by any other drying means known in the prior art.
- the drying of the solid can be carried out in air at a temperature from about 30°C to about 60°C or can be changed accordingly depending on the drying parameters (drying hours and drying temperature) used by a person of ordinary skill in the art.
- the candesartan or its derivatives, including candesartan cilexetil, as obtained by the process described above contains the desethyl impurity at a content of less than 0.6%, preferably less than 0.5% , additionally, the purity is greater than or equal to about 98% when measured by HPLC area percentage.
- the candesartan derivatives obtained above can be further purified in a ketonic solvent and/or a mixture with water under heat.
- ketonic solvent may include acetone, 2-butanone, 2-pentanone, 3- pentanone, 2-hexanone, 2-heptanone, 2-octanone and/or mixtures thereof.
- the heating of the above solution may be carried out at a temperature of from about 35°C to about 50°C and is followed by the addition of water, optionally at the same temperature.
- the reaction mixture may be slowly cooled to a temperature range of about 0°C to about 15°C and is stirred for several hours, for example 2 hours to 5 hours.
- the product obtained during or after stirring can be isolated through conventional means known to a person of ordinary skill in the art including decantation, filtration or centrifugation.
- the solid so obtained can be further purified in a mixture of a ketonic solvent and water as mentioned above.
- the isolated solid can be dried under a vacuum, air or by any other drying means known in the art.
- the drying of the solid can be carried out in air at a temperature from about 30°C to about 50°C.
- the candesartan or its derivatives including candesartan cilexetil as obtained above after purification, has a desethyl impurity content of less than 0.2%, preferably less than 0.1%; and has a purity greater than 99% when measured by HPLC area percentange.
- the present invention also provides a process for the preparation of candesartan cilexetil including the steps of:
- the present invention also provides for candesartan cilexetil having a desethyl impurity content of less than 0.4%, and preferably less than 0.05%.
- the present invention also provides candesartan cilexetil having purity greater than 99%, preferably greater 99.7%
- the candesartan cilexetil obtained as per the present invention can be further purified in an alcoholic solvent.
- the process includes the heating of the reaction mixture from about 35°C to about reflux temperature followed by the cooling of the reaction mixture to a temperature range of about 5°C to about 20°C, stirring for about 4 hours to 8 hours, isolation of the solid using conventional means, for example, decantation, filtration, centrifugation or evaporation and drying under vacuum and/or air.
- the final product obtained as per the procedures of the present invention is in any crystalline or amorphous form, preferably in C- type crystal.
- the present invention provides candesartan cilexetil having purity greater than 99%, more preferably greater than 99.6%, most preferably greater than 99.7% when measured by HPLC area percentage.
- HPLC parameters include column name: Hypersil BDS C-18, 3 ⁇ (100 mm X 4.6 mm); Temperature: 30°C; Flow rate: 1.5 mL/min; Injection Volume: 20 ⁇ ; Run time: 65 min, sodium acetate trihydrate (buffer), solvent mixture of acetonitrile and methanol as mobile phase and methanol as diluent.
- Trityl candesartan cilexetil (10 gm, 0.0117moles) was added to a mixture of methanol (100 mL) and iodine (0.3gm, 0.001181 moles) in a round bottom flask and the resulting solution was stirred for 15 minutes at ambient temperature to get a clear solution. The mixture was heated to 57°C to 58°C and stirred for 4 hours to 5 hours at the same
- Crude candesartan cilexetil (7gm) was suspended in acetone (60mL) at ambient temperature and stirred for 15 minutes at the same temperature.
- the resulting solution was filtered to remove insoluble particles and the obtained filtrate was warmed to 35°C to 40°C. This was followed by the addition of de-ionized water (22mL) at the same temperature.
- the resulting mass was slowly cooled to 2°C to 6°C and stirred for a further for 3 hours to 3.5 hours.
- the wet solid was again suspended in a mixture of acetone (47 mL) and de-ionized water (20 mL) at 35°C to 40°C.
- the resulting mass was slowly cooled to 8°C to 12°C and stirred further for 4 hours.
- the solid obtained was filtered, washed with chilled mixture of acetone:de-ionized water (20 mL, 1:1) and air dried at 40°C to give pure candesartan cilexetil.
- Trityl candesartan cilexetil (lOgm) was added to a mixture of iodine (0.3gm, 0.00118 moles), methanol (100 mL) and dichloromethane (lOmL) at ambient temperature. The resulting mixture was heated to 57°C to 58°C and stirred for 90 to 120 minutes at the same temperature to get the clear solution. This was followed by the removal of the solvent mixture under reduced pressure to get residual mass. The residual mass was dissolved in
- the solid (7.0 gm) as obtained above was purified involving Step II of the Example 1 to provide pure candesartan cilexetil.
- Desethyl candesartan cilexetil 0.01%
- reaction mixture was further stirred at 25 °C to 30°C for 30 minutes, the layers were separated and the organic layer was washed with de-ionized water twice (2 X 20mL). This was followed by the removal of the solvent under vacuum at 30°C to 32°C.
- Methyl tertiarybutyl ether 50mL; MTBE was added at 25 °C to 30°C, the reaction mixture was stirred for 14 hours, the solid was filtered and washed with the same solvent (lOmL) and dried under vacuum at 35°C to 40°C for 8 hours to 12 hours.
- Desethyl candesartan cilexetil 0.04%
- Candesartan cilexetil (2.5gm) obtained from Step 1 was heated in methanol (22.5mL) in a round bottom flask at 35°C to 40°C followed by the cooling of the reaction mixture to 13°C to 17°C over 40 minutes. The reaction mixture was stirred further for 6.5 hours and then filtrated wherein the solid was washed with chilled methanol (ImL) and dried under vacuum at 35°C to 40°C for 12 hours.
- Step I of the Example 3 was repeated using cyclohexane instead of methyl tertiarybutyl ether for the isolation of the crude candesartan cilexetil (5.2 gm) which was further purified as per description provided in Example 3 to provide pure candesartan cilexetil.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention provides an improved process for the preparation of candesartan and pharmaceutically acceptable salts and esters thereof for use in the treatment of hypertension and related diseases. Specifically, it refers to the deprotection of tetrazolyl -protecting group of candesartan or its derivative in the presence of iodine in one or more alcoholic solvents.
Description
PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
Field of the Invention
The present invention provides an improved process for the preparation of
candesartan and pharmaceutically acceptable salts and esters thereof for use in the treatment of hypertension and related diseases.
Background of the Invention
Candesartan cilexetil of Formula I is a prodrug and is chemically described as (±)-l- Hydroxyethyl-2-ethoxy- 1 - [p-(o- lHtetrazol-5-ylphenyl)benzyl] -7-benzimidazole carboxylate, cyclohexyl carbonate (ester). It is a selective angiotensin II receptor antagonist and is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents and is represented by the structural Formula I as shown below.
Formula I
U.S. Patent Nos. 5,196,444 and 5,578,733 describe the removal of a trityl protecting group of the N-protected tetrazolyl compounds using methanol in the presence of a mineral acid, such as hydrochloric acid, which requires complex extractions or chromatographic purification to produce pure candesartan cilexetil.
U.S. Patent No. 7,345,072 describes the deprotection of tetrazolyl compounds, including candesartan cilexetil, in the presence of an anhydrous mineral acid or aqueous mineral acid at a concentration higher than 20% w/w. The strong acidic conditions produce more decomposition products and thereby reduces the overall purity of the final product.
WO 05/021535 discloses the preparation of candesartan cilexetil by the deprotection of trityl moiety at a reflux temperature in the presence of anhydrous Ci to C5 alcohol under neutral or slightly basic conditions involving longer reaction time (for e.g. stirring for several hours, such as 18-24 hours); this is followed by removal of the triphenylmethylether moiety precipitated as a solid, and thereby increases the number of reaction steps.
WO 05/037821 describes the deprotection of the trityl candesartan cilexetil by the use of methane sulphonic acid, p-toluene sulphonic acid, formic and trifluoroacetic acid in solvent mixture or by refluxing candesartan cilexetil in mixture of toluene, water, and methanol. The initial product obtained by these procedures is mostly a viscous oil or a semi solid, which is difficult to handle.
WO 07/074399 and WO 07/042161 disclose the preparation of candesartan cilexetil from trityl candesartan cilexetil involving Lewis acids such as boron trifluoride, zinc chloride, aluminium trihalide, or titanium tetrachloride which are costly and thus are not commercially viable.
The present inventors have now found an improved process for the preparation of candesartan or its derivatives which is simple, convenient to operate, and uses readily available raw materials.
Summary of the Invention
In one general aspect, the present invention provides for a process for the preparation of candesartan or its derivatives. The process includes:
(a) removing a tetrazolyl-protecting group of candesartan or its derivative in the presence of iodine in one or more alcoholic solvents;
(b) optionally adding a second solvent;
(c) heating the reaction mixture; and
(d) isolating candesartan or its derivative.
Embodiments of this aspect may include one or more of the following features. For example, the alcoholic solvent used in step (a) may include methanol, ethanol, n-propanol, n- butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and/or mixtures thereof. The second solvent may be chloroform, dichloromethane, carbon tetrachloride, ethylene dichloride and/or mixtures thereof.
The heating of the reaction mixture is carried out at the temperature from about 35°C to about reflux temperature. The stirring of the reaction mixture is carried out from about 1 hour to about 10 hours. The isolation of the solid obtained in step (d) involves purification from a suitable organic solvent that includes the heating of the mixture at the temperature from about 25°C to about 45°C.
The suitable organic solvent may be either ethers and/or hydrocarbon solvents. The ether may be methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane and/or mixtures thereof. The hydrocarbon solvent may be pentane, hexane, n-heptane, n-octane,
cyclopentane, cyclohexane, benzene, toluene or o, m, p- xylenes.
The drying of the solid is carried out in air at a temperature from about 30°C to about 60°C. The purification from a ketonic solvent or a mixture with water involves heating from about 35°C to about 50°C. The ketonic solvent is selected from the group of acetone, 2- butanone, 2-pentanone, 3-pentanone, 2-hexanone, 2-heptanone, 2-octanone and/or mixtures thereof.
The isolation of the solid includes the cooling of the reaction mixture from about 0°C to about 15°C. The isolation may further include drying the solid in air at the temperature from about 30°C to about 50°C.
In another general aspect, the present invention includes a process for the preparation of candesartan or its derivatives. The process includes:
(a) treating trityl candesartan cilexetil having the structure of Formula II
Formula II
with iodine in an alcoholic solvent or mixtures;
(b) optionally adding a second solvent;
(c) heating the reaction mixture; and
(d) isolating candesartan cilexetil.
Embodiments of this aspect may include one or more of the following features. For example, the alcoholic solvent used in step (a) may be methanol, ethanol, n-propanol, n- butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and/or mixtures thereof. The second solvent includes chloroform, dichloromethane, carbon tetrachloride, ethylene dichloride and/or mixtures thereof.
The heating of the reaction mixture is carried out at the temperature from about 35°C to about reflux temperature. The stirring of the reaction mixture is carried out from about 1
hour to about 10 hours. The isolation of the solid obtained in step (b) involves purification from a suitable organic solvent that includes the heating of the mixture at the temperature from about 25 °C to about 45 °C. The suitable organic solvent may be ethers and/or hydrocarbon solvents. The ether may be methyl tertiary butyl ether, tetrahydrofuran, 1,4- dioxane and/or mixtures thereof. The hydrocarbon solvent may be pentane, hexane, n- heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene or o, m, p- xylenes.
The purification from a ketonic solvent or its mixture with water involves heating from about 35°C to about 50°C. The ketonic solvent is selected from the group of acetone, 2- butanone, 2-pentanone, 3-pentanone, 2-hexanone, 2-heptanone, 2-octanone and/or mixtures thereof.
The isolation of the solid includes the cooling of the reaction mixture from about 0°C to about 15°C. The process further includes drying the solid in air at the temperature from about 30°C to about 50°C.
In another general aspect, the present invention provides for candesartan cilexetil comprising HPLC purity greater than 99% and desethyl impurity content less than 0.2%.
Detailed Description of the Invention
The present invention provides for a process for the preparation of candesartan or its derivatives, which includes the steps of:
(a) removing the tetrazolyl-protected group of candesartan or its derivative in the presence of iodine, in one or more alcoholic solvents;
(b) optionally adding a second solvent; and heating the reaction mixture; and
(c) isolating candesartan or its derivative.
The alcoholic solvent can be selected from methanol, ethanol, n-propanol, n-butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol or a mixture thereof. The second solvent in step (b) can be selected from chloroform, dichloromethane, carbontetrachloride, ethylene dichloride and/or mixtures thereof.
The present invention also included candesartan or its derivatives as obtained above, including candesartan cilexetil containing a desethyl impurity content less than 0.6%, preferably less than 0.5% and a purity greater than or equal to about 98% when measured by HPLC area percentage.
Candesartan or its derivatives may be purified from a ketonic solvent or their mixtures and/or a mixture with water.
"Derivatives of candesartan" herein refers to pharmaceutically acceptable salts and esters.
The reaction mixture containing a tetrazolyl protected derivative of candesartan in an alcoholic solvent or their mixtures in the presence of iodine can be heated from about 35°C to about reflux temperature followed by stirring.
As used herein, the term "about" when used in reference to defined parameter like temperature, indicates inherent variability in, for example, measuring the parameter or achieving the parameter and refers to variation by +5°C.
"Reflux temperature" herein refers to the temperature at which solvent/solvent mixture starts boiling.
The term "tetrazolyl protecting group" as used herein may include, but is not limited groups including optionally substituted multiphenylmethyl groups (e.g., triphenylmethyl (trityl), 4-methoxy triphenylmethyl, 4,4'-dimethoxytriphenylmethyl, 4,4',4"- trimethoxytriphenyl methyl, 4,4'-dimethoxydiphenyl methyl and the like), 2- nitrobenzenesulfenyl and benzhydryl.
The solution of iodine in an alcoholic solvent or mixtures thereof can be prepared at room temperature (25 °C to 30°C) or by heating.
Alcoholic solvent may include Ci-C8 straight or branched chain alcohols which can be primary, secondary, tertiary, comprising of methanol, ethanol, n-propanol, isopropanol, n- butanol, isobutanol, ter-butanol, n-pentanol, n-hexanol, n-heptanol, n-octanol and the like.
The second solvent used herein is a halogenated solvent which may be optionally added to the alcoholic mixture of tetrazolyl-protected candesartan and iodine, examples of which may include chloroform, dichloromethane, carbontetrachloride, ethylene dichloride and/or mixtures thereof. It is generally observed that the addition of the second solvent helps in increasing the final purity of the candesartan or its derivatives including candesartan cilexetil.
The stirring of the above reaction mixture containing the tetrazolyl protected derivative of candesartan and iodine in an alcoholic solvent may be carried out for about 1 hour to about 10 hours to get a clear solution at the same temperature. Stirring time may be changed accordingly, depending upon the temperature used for heating by a person of ordinary skill in the art.
The solvent/solvent mixture may be removed to get the residual solid material. The removal of the solvent/solvent mixture may be carried out by any means known to a person of ordinary skill in the art, including for example concentration, evaporation or distillation.
The residual solid material can be further dissolved in a halogenated solvent followed by washing with an aqueous sodium thiosulfate solution and de-ionized water. Examples of halogenated solvents are as described above.
The organic layer so obtained may be dried over sodium sulfate and concentrated under reduced pressure and/or optionally charcolized with active carbon. This is followed by filtration over hyflobed to get solid mass, which then may be further dissolved in a suitable organic solvent, for purification from about ambient temperature to about 45 °C and stirred for about 7 hours to about 15 hours at the same temperature.
"Ambient temperature" herein refers to room temperature (25°C to 30°C).
Examples of suitable organic solvents may include ethers, such as, methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane or aliphatic, alicyclic and aromatic hydrocarbons, such as, pentane, hexane, n-heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene, o, m, p-xylenes and the like.
The product obtained after stirring can be isolated by any conventional means known to a person of ordinary skill in the art including decantation, filtration or centrifugation.
The isolated solid can be dried under vacuum and/or air or by any other drying means known in the prior art. The drying of the solid can be carried out in air at a temperature from about 30°C to about 60°C or can be changed accordingly depending on the drying parameters (drying hours and drying temperature) used by a person of ordinary skill in the art.
The candesartan or its derivatives, including candesartan cilexetil, as obtained by the process described above contains the desethyl impurity at a content of less than 0.6%,
preferably less than 0.5% , additionally, the purity is greater than or equal to about 98% when measured by HPLC area percentage.
The candesartan derivatives obtained above can be further purified in a ketonic solvent and/or a mixture with water under heat.
Examples of ketonic solvent may include acetone, 2-butanone, 2-pentanone, 3- pentanone, 2-hexanone, 2-heptanone, 2-octanone and/or mixtures thereof.
The heating of the above solution may be carried out at a temperature of from about 35°C to about 50°C and is followed by the addition of water, optionally at the same temperature. The reaction mixture may be slowly cooled to a temperature range of about 0°C to about 15°C and is stirred for several hours, for example 2 hours to 5 hours.
The product obtained during or after stirring can be isolated through conventional means known to a person of ordinary skill in the art including decantation, filtration or centrifugation. The solid so obtained can be further purified in a mixture of a ketonic solvent and water as mentioned above.
The isolated solid can be dried under a vacuum, air or by any other drying means known in the art. The drying of the solid can be carried out in air at a temperature from about 30°C to about 50°C.
The candesartan or its derivatives, including candesartan cilexetil as obtained above after purification, has a desethyl impurity content of less than 0.2%, preferably less than 0.1%; and has a purity greater than 99% when measured by HPLC area percentange.
The present invention also provides a process for the preparation of candesartan cilexetil including the steps of:
(a) treating trityl candesartan cilexetil with iodine in an alcoholic solvent;
(b) optionally adding a second solvent and heating the reaction mixture; and
(c) isolating candesartan cilexetil.
The present invention also provides for candesartan cilexetil having a desethyl impurity content of less than 0.4%, and preferably less than 0.05%.
The present invention also provides candesartan cilexetil having purity greater than 99%, preferably greater 99.7%
The candesartan cilexetil obtained as per the present invention can be further purified in an alcoholic solvent. The process includes the heating of the reaction mixture from about 35°C to about reflux temperature followed by the cooling of the reaction mixture to a temperature range of about 5°C to about 20°C, stirring for about 4 hours to 8 hours, isolation of the solid using conventional means, for example, decantation, filtration, centrifugation or evaporation and drying under vacuum and/or air. The final product obtained as per the procedures of the present invention is in any crystalline or amorphous form, preferably in C- type crystal.
The present invention provides candesartan cilexetil having purity greater than 99%, more preferably greater than 99.6%, most preferably greater than 99.7% when measured by HPLC area percentage. The HPLC parameters include column name: Hypersil BDS C-18, 3μπι (100 mm X 4.6 mm); Temperature: 30°C; Flow rate: 1.5 mL/min; Injection Volume: 20 μί; Run time: 65 min, sodium acetate trihydrate (buffer), solvent mixture of acetonitrile and methanol as mobile phase and methanol as diluent.
In the following section preferred embodiments are described by way of examples to illustrate the process. However, these are not intended in any way to limit the scope of the claims. Several variants of these examples would be evident to persons ordinarily skilled in the art.
EXAMPLES
Example 1: Preparation of Candesartan Cilexetil Step I:
Trityl candesartan cilexetil (10 gm, 0.0117moles) was added to a mixture of methanol (100 mL) and iodine (0.3gm, 0.001181 moles) in a round bottom flask and the resulting solution was stirred for 15 minutes at ambient temperature to get a clear solution. The mixture was heated to 57°C to 58°C and stirred for 4 hours to 5 hours at the same
temperature, followed by removal of the methanol under reduced pressure, to get the residual mass. The residual mass so obtained was dissolved in dichloromethane (60mL) and washed with a 5% aqueous sodium thiosulfate (lOOmL) solution followed by washing of the organic
layer with de-ionized water (40 mL). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to get the residual mass. This was followed by the addition of cyclohexane (lOOmL) and subsequent stirring for 12 hours at ambient
temperature. The solid obtained was filtered, washed with cyclohexane (20mL) and air dried at 40°C to get crude candesartan cilexetil.
Yield: 7.45 gm
Step II:
Purification of candesartan cilexetil:
Crude candesartan cilexetil (7gm) was suspended in acetone (60mL) at ambient temperature and stirred for 15 minutes at the same temperature. The resulting solution was filtered to remove insoluble particles and the obtained filtrate was warmed to 35°C to 40°C. This was followed by the addition of de-ionized water (22mL) at the same temperature. The resulting mass was slowly cooled to 2°C to 6°C and stirred for a further for 3 hours to 3.5 hours. The wet solid was again suspended in a mixture of acetone (47 mL) and de-ionized water (20 mL) at 35°C to 40°C. The resulting mass was slowly cooled to 8°C to 12°C and stirred further for 4 hours. The solid obtained was filtered, washed with chilled mixture of acetone:de-ionized water (20 mL, 1:1) and air dried at 40°C to give pure candesartan cilexetil.
Yield: 3.97gm
Chromatographic purity: 99.34%
Desethyl candesartan cilexetil: 0.29%
Example 2: Preparation of Candesartan Cilexetil
Trityl candesartan cilexetil (lOgm) was added to a mixture of iodine (0.3gm, 0.00118 moles), methanol (100 mL) and dichloromethane (lOmL) at ambient temperature. The resulting mixture was heated to 57°C to 58°C and stirred for 90 to 120 minutes at the same temperature to get the clear solution. This was followed by the removal of the solvent mixture under reduced pressure to get residual mass. The residual mass was dissolved in
dichloromethane (lOOmL), washed with 5% aqueous sodium thiosulfate (40mL) solution, and washed with de-ionized water twice (2 X 20 mL). The organic layer was dried over sodium sulfate and charcoalized with activated carbon (0.25gm) followed by filtration over hyflo bed.
The obtained filtrate was concentrated under reduced pressure to get the residual mass. Cyclohexane (lOOmL) was added and the resulting reaction mixture was stirred for 12 hours at ambient temperature. The solid obtained was filtered, washed with cyclohexane (20mL) and air dried at 40°C to 45°C to get crude candesartan cilexetil.
Yield: 7.2 gm
The solid (7.0 gm) as obtained above was purified involving Step II of the Example 1 to provide pure candesartan cilexetil.
Yield: 5.68g
Chromatographic purity: 99.72%
Desethyl candesartan cilexetil: 0.01%
Example 3: Preparation of Candesartan Cilexetil Step I:
Methanol (20mL) and iodine (0.2966gm) were stirred in a round bottom flask for 15 minutes at 25°C to 30°C to get clear solution. This was followed by the addition of N-trityl candesartan cilexetil (lOgm) and dichloromethane (40mL). The reaction mixture was heated to reflux at 38°C to 40°C for 9 hours, followed by concentration of the reaction mass under vacuum at 30°C to 35°C to get the dark brown colour residue. To the obtained residue dichloromethane (lOOmL) was added, and the mixture was stirred to get clear solution followed by washing with 5% aqueous sodium thiosulphate (2.5gm in 50mL of de-ionized water). The reaction mixture was further stirred at 25 °C to 30°C for 30 minutes, the layers were separated and the organic layer was washed with de-ionized water twice (2 X 20mL). This was followed by the removal of the solvent under vacuum at 30°C to 32°C. Methyl tertiarybutyl ether (50mL; MTBE) was added at 25 °C to 30°C, the reaction mixture was stirred for 14 hours, the solid was filtered and washed with the same solvent (lOmL) and dried under vacuum at 35°C to 40°C for 8 hours to 12 hours.
Dry Weight: 5.4 gm
Yield: 0.54 w/w
Chromatographic Purity: 98.92%
Desethyl candesartan cilexetil: 0.18%
The solid (4.0 gm) as obtained above was purified involving Step II of the Example 1 to provide pure candesartan cilexetil.
Dry weight: 3.4g Yield: 0.85 w/w
Chromatographic purity: 99.32%
Desethyl candesartan cilexetil: 0.04%
Step II:
Candesartan cilexetil (2.5gm) obtained from Step 1 was heated in methanol (22.5mL) in a round bottom flask at 35°C to 40°C followed by the cooling of the reaction mixture to 13°C to 17°C over 40 minutes. The reaction mixture was stirred further for 6.5 hours and then filtrated wherein the solid was washed with chilled methanol (ImL) and dried under vacuum at 35°C to 40°C for 12 hours.
Dry weight: 2.2 gm
Yield: 0.88 w/w
Chromatographic purity: 99.79%
Desethyl candesartan: 0.018%
Example 4:
Step I of the Example 3 was repeated using cyclohexane instead of methyl tertiarybutyl ether for the isolation of the crude candesartan cilexetil (5.2 gm) which was further purified as per description provided in Example 3 to provide pure candesartan cilexetil.
Dry weight: 1.32 gm
Yield: 0.88 w/w
Chromatographic purity: 99.15%
Desethyl candesartan cilexetil: 0.19%
Claims
1. A process for the preparation of candesartan or its derivatives, the process
comprising:
(a) removing a tetrazolyl-protecting group of candesartan or its derivative in the presence of iodine in one or more alcoholic solvents;
(b) optionally adding a second solvent;
(c) heating the reaction mixture; and
(d) isolating candesartan or its derivative.
2. The process according to claim 1, wherein the alcoholic solvent used in step (a)
comprises methanol, ethanol, n-propanol, n-butanol, n-pentanol, n-hexanol, n- heptanol, n-octanol and/or mixtures thereof.
3. The process according to claim 1, wherein the second solvent comprises chloroform, dichloromethane, carbon tetrachloride, ethylene dichloride and/or mixtures thereof.
4. The process according to claim 1, wherein the heating of the reaction mixture is
carried out at the temperature from about 35°C to about reflux temperature.
5. The process according to claim 1, wherein the stirring of the reaction mixture is
carried out from about 1 hour to about 10 hours.
6. The process according to claim 1, wherein the isolation of the solid obtained in step (d) involves purification from a suitable organic solvent comprising the heating of the mixture at the temperature from about 25 °C to about 45 °C.
7. The process according to claim 6, wherein the suitable organic solvent comprises ethers and/or hydrocarbon solvents.
8. The process according to claim 7, wherein the ether comprises methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane and/or mixtures thereof.
9. The process according to claim 7, wherein the hydrocarbon solvent comprises
pentane, hexane, n-heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene or o, m, p- xylenes.
10. The process according to claim 7, wherein the drying of the solid is carried out in air at a temperature from about 30°C to about 60°C.
11. The process according to claim 7, wherein the purification from a ketonic solvent or a mixture with water involves heating from about 35°C to about 50°C. RI-WO 2011/080684 PCT/IB2010/056066
13 12. The process according to claim 11, wherein the ketonic solvent is selected from the group comprising of acetone, 2-butanone, 2-pentanone, 3-pentanone, 2-hexanone, 2- heptanone, 2-octanone and/or mixtures thereof.
13. The process according to claim 1, wherein the isolation of the solid comprises cooling of the reaction mixture from about 0°C to about 15°C.
14. The process according to claim 13, further comprising drying the solid in air at the temperature from about 30°C to about 50°C.
15. A process for the preparation of candesartan or its derivatives, the process
comprising:
(a) treating trityl candesartan cilexetil having the structure of Formula II
Formula II
with iodine in an alcoholic solvent or mixtures;
(b) optionally adding a second solvent;
(c) heating the reaction mixture; and
(d) isolating candesartan cilexetil.
16. The process according to claim 15, wherein the alcoholic solvent used in step (a) comprises methanol, ethanol, n-propanol, n-butanol, n-pentanol, n-hexanol, n- heptanol, n-octanol and/or mixtures thereof.
17. The process according to claim 15, wherein the second solvent comprises chloroform, dichloromethane, carbon tetrachloride, ethylene dichloride and/or mixtures thereof.
18. The process according to claim 15, wherein the heating of the reaction mixture is carried out at the temperature from about 35°C to about reflux temperature.
19. The process according to claim 15, wherein the stirring of the reaction mixture is carried out from about 1 hour to about 10 hours.
20. The process according to claim 15, wherein the isolation of the solid obtained in step (b) involves purification from a suitable organic solvent comprising the heating of the mixture at the temperature from about 25°C to about 45°C. RI-WO 2011/080684 PCT/IB2010/056066
14 21. The process according to claim 20, wherein the suitable organic solvent comprises ethers and/or hydrocarbon solvents.
22. The process according to claim 21, wherein the ether comprises methyl tertiary butyl ether, tetrahydrofuran, 1,4-dioxane and/or mixtures thereof.
23. The process according to claim 21, wherein the hydrocarbon solvent comprises
pentane, hexane, n-heptane, n-octane, cyclopentane, cyclohexane, benzene, toluene or o, m, p- xylenes.
24. The process according to claim 20, wherein the purification from a ketonic solvent or its mixture with water involves heating from about 35°C to about 50°C.
25. The process according to claim 24, wherein the ketonic solvent is selected from the group comprising of acetone, 2-butanone, 2-pentanone, 3-pentanone, 2-hexanone, 2- heptanone, 2-octanone and/or mixtures thereof.
26. The process according to claim 15 , wherein the isolation of the solid comprises the cooling of the reaction mixture from about 0°C to about 15°C.
27. The process according to claim 26, further comprising drying the solid in air at the temperature from about 30°C to about 50°C.
28. Candesartan cilexetil comprising a HPLC purity greater than 99% and desethyl
impurity content less than 0.2%.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2746/DEL/2009 | 2009-12-31 | ||
IN2746DE2009 | 2009-12-31 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011080684A1 true WO2011080684A1 (en) | 2011-07-07 |
WO2011080684A4 WO2011080684A4 (en) | 2011-09-01 |
WO2011080684A9 WO2011080684A9 (en) | 2011-10-20 |
Family
ID=43825390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/056066 WO2011080684A1 (en) | 2009-12-31 | 2010-12-23 | Process for the preparation of candesartan cilexetil |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011080684A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111909136A (en) * | 2020-08-21 | 2020-11-10 | 珠海润都制药股份有限公司 | Preparation method of candesartan cilexetil |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5578733A (en) | 1994-01-28 | 1996-11-26 | Takeda Chemical Industries, Ltd. | Process for the production of tetrazolyl compounds |
WO2005021535A2 (en) | 2003-08-27 | 2005-03-10 | Zentiva, A.S. | A method of removing the triphenylmethane protecting group |
WO2005037821A2 (en) | 2003-10-16 | 2005-04-28 | Teva Pharmaceutical Industries Ltd. | Preparation of candesartan cilexetil |
WO2007042161A1 (en) | 2005-10-07 | 2007-04-19 | Krka, D.D. Novo Mesto | Process for the preparation of candesartan cilexetil |
WO2007074399A2 (en) | 2005-06-06 | 2007-07-05 | Medichem, S.A. | Process for the preparation of tetrazolyl compounds |
US7345072B2 (en) | 2003-11-28 | 2008-03-18 | Dipharma S.P.A. | Phenyltetrazole compounds |
-
2010
- 2010-12-23 WO PCT/IB2010/056066 patent/WO2011080684A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
US5578733A (en) | 1994-01-28 | 1996-11-26 | Takeda Chemical Industries, Ltd. | Process for the production of tetrazolyl compounds |
WO2005021535A2 (en) | 2003-08-27 | 2005-03-10 | Zentiva, A.S. | A method of removing the triphenylmethane protecting group |
WO2005037821A2 (en) | 2003-10-16 | 2005-04-28 | Teva Pharmaceutical Industries Ltd. | Preparation of candesartan cilexetil |
US7345072B2 (en) | 2003-11-28 | 2008-03-18 | Dipharma S.P.A. | Phenyltetrazole compounds |
WO2007074399A2 (en) | 2005-06-06 | 2007-07-05 | Medichem, S.A. | Process for the preparation of tetrazolyl compounds |
WO2007042161A1 (en) | 2005-10-07 | 2007-04-19 | Krka, D.D. Novo Mesto | Process for the preparation of candesartan cilexetil |
Non-Patent Citations (1)
Title |
---|
RAMASAMY K S ET AL: "A simple and convenient method for the deprotection of tetrahydropyranyl ether using iodine in methanol", SYNTHETIC COMMUNICATIONS 1999 US, vol. 29, no. 16, 1999, pages 2881 - 2894, XP002632165, ISSN: 0039-7911 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111909136A (en) * | 2020-08-21 | 2020-11-10 | 珠海润都制药股份有限公司 | Preparation method of candesartan cilexetil |
Also Published As
Publication number | Publication date |
---|---|
WO2011080684A4 (en) | 2011-09-01 |
WO2011080684A9 (en) | 2011-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2141175C (en) | A process for the production of tetrazolyl compounds | |
JP6538556B2 (en) | Crystalline complex of 1-cyano-2- (4-cyclopropyl-benzyl) -4-(. Beta.-D-glucopyranose-1-yl) -benzene, process for its preparation and its use for preparing a drug | |
WO2007048361A1 (en) | A method of removing the triphenylmethane protecting group from precursors of antihypertensive drugs | |
US20090247595A1 (en) | Process for the preparation of tetrazolyl compounds | |
WO2016178148A1 (en) | Process for preparation of dapagliflozin | |
US9273010B2 (en) | Process for bendamustine hydrochloride | |
WO2018224923A1 (en) | Process for preparation of crisaborole | |
WO2005051943A1 (en) | Processes for the preparation of highly pure irbesartan | |
US20120029201A1 (en) | Process for the preparation of candesartan cilexetil | |
WO2011080684A1 (en) | Process for the preparation of candesartan cilexetil | |
US20160002275A1 (en) | Process for preparation and purification of canagliflozin | |
WO2007088558A2 (en) | A process for purification of valsartan | |
WO2017131218A1 (en) | Azilsartan and method for producing same | |
EP2303870A2 (en) | Process for preparation of candesartan cilexetil | |
EP1984356B1 (en) | An improved process for the preparation of candesartan cilexetil | |
WO2010004385A1 (en) | Process for the preparation of pure 4'-[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid | |
US20220274942A1 (en) | Methods of preparing synthetic cannabinol and homologs thereof | |
WO2005051928A1 (en) | Process for production of tetrazolyl compounds | |
AU2010250827A1 (en) | Process for the preparation of olmesartan medoxomil | |
US20130096275A1 (en) | Vancomycin b hydrochloride crystalline form 1 | |
US9499491B2 (en) | One pot process for the preparation of telmisartan | |
CN109790172B (en) | Process for the isolation and purification of naltrexone | |
WO2011092666A1 (en) | An improved process for the preparation of candesartan cilexetil, polymorphic forms of n-trityl candesartan and their uses thereof | |
WO2009072137A2 (en) | Process for pure irbesartan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10814710 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10814710 Country of ref document: EP Kind code of ref document: A1 |